Genocea Biosciences Inc. buy stratec
Summary
This prediction ended on 06.09.18 with a price of €4.33. The BUY prediction by stratec for Genocea Biosciences Inc. performed very badly with a performance of -51.60%. stratec has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - |
| iShares Core DAX® | -4,93 % | -11,98 % | -3,49 % | 44,54 % |
| iShares Nasdaq 100 | -2,63 % | -2,22 % | 13,78 % | 80,99 % |
| iShares Nikkei 225® | -4,73 % | -10,90 % | 19,71 % | 45,26 % |
| iShares S&P 500 | -2,54 % | -3,54 % | 8,88 % | 61,12 % |
Comments by stratec for this prediction
In the thread Genocea Biosciences Inc. diskutieren
Genocea : Cantor sees five-bagger potential
Cantor Fitzgerald set a Street-high price target of $5, suggesting a near-quintupling from today's close of $1.03.